In a significant boost for 23andMe, the Food and Drug Administration has allowed the direct-to-consumer genetics Silicon Valley startup to use its kit to test for a serious genetic disorder known as Bloom Syndrome.

In November 2013, the FDA ordered 23andMe to stop marketing and selling its kits as a way to test for genetic health information. This marks the first time the FDA has allowed for a home “carrier screening” genetic test. (Ars examined the state of direct-to-consumer genetic testing in April 2014.) Since the 2013 ban, 23andMe customers could only use the service as a way to find out more about their genealogy.

According to the National Institutes of Health, Bloom Syndrome “is an inherited disorder characterized by short stature, sun-sensitive skin changes, an increased risk of cancer, and other health problems.”

“The FDA believes that in many circumstances it is not necessary for consumers to go through a licensed practitioner to have direct access to their personal genetic information,” said Alberto Gutierrez, a director at the FDA’s Center for Devices and Radiological Health, in a statement on Thursday.

“Today’s authorization and accompanying classification, along with FDA’s intent to exempt these devices from FDA premarket review, supports innovation and will ultimately benefit consumers," Gutierrez said. "These tests have the potential to provide people with information about possible mutations in their genes that could be passed on to their children.”

In a statement on Thursday, 23andMe CEO Anne Wojcicki said, “While this authorization is for a single carrier status test only, we are committed to providing US customers with health information once more tests have been through this process and we have a more comprehensive product offering.”